NOVN.CH

97.19

+0.51%↑

SOON.CH

255.8

+1.07%↑

NOVN.CH

97.19

+0.51%↑

SOON.CH

255.8

+1.07%↑

NOVN.CH

97.19

+0.51%↑

SOON.CH

255.8

+1.07%↑

NOVN.CH

97.19

+0.51%↑

SOON.CH

255.8

+1.07%↑

NOVN.CH

97.19

+0.51%↑

SOON.CH

255.8

+1.07%↑

Search

Roche Holding AG

Suletud

SektorTervishoid

286.8 0.14

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

286

Max

286.8

Põhinäitajad

By Trading Economics

Sissetulek

-4.2B

2B

Müük

-109M

31B

P/E

Sektori keskmine

27.255

51.198

Dividenditootlus

3.45

Kasumimarginaal

6.588

Töötajad

103,249

EBITDA

-4.6B

6B

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.45%

2.40%

Turustatistika

By TradingEconomics

Turukapital

-6.2B

213B

Eelmine avamishind

286.66

Eelmine sulgemishind

286.8

Uudiste sentiment

By Acuity

32%

68%

87 / 380 Pingereas Healthcare

Roche Holding AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. mai 2025, 02:16 UTC

Suurimad hinnamuutused turgudel

Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs

24. apr 2025, 07:30 UTC

Tulu

Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push -- Update

24. apr 2025, 05:31 UTC

Tulu

Roche Sales Rise Boosted By Key Drugs

9. apr 2025, 09:39 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

12. märts 2025, 09:23 UTC

Suurimad hinnamuutused turgudel

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

30. jaan 2025, 09:36 UTC

Tulu

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30. jaan 2025, 06:32 UTC

Tulu

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

3. juuni 2025, 07:51 UTC

Market Talk

Roche Unlikely to Get Revenue Boost From Tecentriq Combination With Lurbinectedin -- Market Talk

21. mai 2025, 07:20 UTC

Market Talk

Roche Lymphoma Drug Columvi Dealt Setback by FDA Committee -- Market Talk

2. mai 2025, 06:25 UTC

Market Talk
Tulu

Roche Shows Pipeline Progress But Near-Term Risks Remain -- Market Talk

24. apr 2025, 09:39 UTC

Market Talk
Tulu

Roche's Pipeline in Focus After Solid Results -- Market Talk

24. apr 2025, 09:24 UTC

Market Talk
Tulu

Roche's Reiterated Outlook Looks Reassuring -- Market Talk

24. apr 2025, 09:18 UTC

Market Talk
Tulu

Roche's Results Are Solid -- Market Talk

24. apr 2025, 05:16 UTC

Peamised uudised

Roche Sales Rise, Boosted By Key Drugs

22. apr 2025, 10:51 UTC

Peamised uudised

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

15. apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9. apr 2025, 10:03 UTC

Market Talk
Tulu

Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk

9. apr 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3. apr 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3. apr 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31. märts 2025, 09:31 UTC

Kuumad aktsiad

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

13. märts 2025, 07:46 UTC

Market Talk

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

12. märts 2025, 16:34 UTC

Peamised uudised

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12. märts 2025, 08:51 UTC

Market Talk

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

12. märts 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

13. veebr 2025, 11:43 UTC

Market Talk

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30. jaan 2025, 07:56 UTC

Market Talk
Tulu

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30. jaan 2025, 06:04 UTC

Tulu

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

30. jaan 2025, 06:04 UTC

Tulu

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

30. jaan 2025, 06:04 UTC

Tulu

Roche Issues 2025 View

Võrdlus sarnastega

Hinnamuutus

Roche Holding AG Prognoos

Sentiment

By Acuity

87 / 380 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.